PharmaShots | Incisive News in 3 Shots

Subscribe Now

amylyx pharmaceuticals

Amylyx Pharmaceuticals Reports the First Participant Dosing in P-III (LUCIDITY) Study Evaluating Avexitide in PBH

Amylyx Pharmaceuticals Reports the First Participant Dosing in P-III (LUCIDITY) Study Evaluating Avexitide in PBH

May 1, 2025

Amylyx Pharmaceuticals’ AMX0035 Gains the EC’s Orphan Drug Designation to Treat Wolfram Syndrome

Amylyx Pharmaceuticals’ AMX0035 Gains the EC’s Orphan Drug Designation to Treat Wolfram Syndrome

August 5, 2024

Amylyx Pharmaceuticals Reports the First Patient Dosing with AMX0035 in P-III Trial for the Treatment of Progressive Supranuclear Palsy (PSP)

Amylyx Pharmaceuticals Reports the First Patient Dosing with AMX0035 in P-III Trial for the Treatment of Progressive Supranuclear...

December 25, 2023

Amylyx Pharmaceuticals Entered into an Exclusive Distribution Agreement with Neopharm for AMX0035

Amylyx Pharmaceuticals Entered into an Exclusive Distribution Agreement with Neopharm for AMX0035

January 17, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us